Starpharma Holdings Ltd has released a press release.
First Asian Regulatory Approvals Received for VivaGel BV
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Story so far
Earlier from Starpharma
- Starpharma commences phase 1/2 DEP irinotecan trial
- VivaGel BV launched in Europe
- Starpharma signs second oncology agreement with AstraZeneca
- DEP irinotecan combination outperforms in colon cancel model
- First VivaGel BV launch globally in Australia by Aspen
Later from Starpharma
- Promising efficacy signals observed in ongoing DEP trials
- Positive results with Targeted DEP using antibody fragment
- VivaGel BV regulatory approvals continue in Asia
- DEP irinotecan synergistic with Lynparza in refractory model
- FDA Authorises Clinical Trial with AstraZeneca DEP product
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma